A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
D000505:Alopecia / Q000139:chemically induced; D001792:Blood Platelets; D001943:Breast Neoplasms / Q000188:drug therapy*; D002369:Castration; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count; D009422:Nervous System Diseases / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010053:Ovary; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D003510:Cyclohexanes; D009607:Nitrosourea Compounds; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone